Modern research into metabolic dysfunction and mitochondrial health has opened the door to a new class of therapies: exercise mimetics. Among these, one molecule stands out—SLU-PP-332. This orally active peptide acts as a potent estrogen-related receptor alpha (ERRα) agonist, mimicking the cellular and physiological effects of aerobic exercise, without requiring intense physical exertion.
In this in-depth article, we explore the mechanism, benefits, ideal users, safety, and therapeutic potential of SLU-PP-332. We’ll also examine the scientific research backing its use for fat loss, glucose control, aging, endurance, mitochondrial rejuvenation, and more.
• Tesamorelin vs Ipamorelin
• Peptides for Muscle Growth and Recovery
• Peptides for Energy and Fatigue
• 5-Amino-1MQ Peptide Therapy
SLU-PP-332 is a synthetic small molecule and oral peptide designed to selectively activate estrogen-related receptors (ERRs)—especially ERRα, a key regulator of energy metabolism and mitochondrial biogenesis. It belongs to a class of compounds known as exercise mimetics because it reproduces many of the metabolic and structural effects of physical activity at the cellular level.
Unlike injectables or performance-enhancing drugs, SLU-PP-332 is taken orally and does not require cycling. It’s well-tolerated, non-hormonal, and does not suppress endogenous production of any key hormone or peptide.
Estrogen-related receptor alpha (ERRα) is a nuclear receptor—not directly involved in estrogen signaling—that plays a critical role in regulating:
Mitochondrial biogenesis
Fatty acid oxidation
Glucose metabolism
Oxidative phosphorylation
Thermogenesis and cellular respiration
It is highly expressed in energy-demanding tissues like skeletal muscle, heart, and brown fat. When activated, ERRα turns on genes that support energy expenditure, fat metabolism, and cellular repair—functions that are naturally boosted during endurance exercise.
SLU-PP-332 binds to and activates ERRα with high affinity, triggering the expression of hundreds of exercise-related genes. These include:
PGC-1α: Master regulator of mitochondrial biogenesis
GLUT4: Glucose transporter upregulated by insulin and exercise
UCPs (uncoupling proteins): Enhance thermogenesis and energy expenditure
Fatty acid oxidation enzymes: Boost lipid metabolism
The result is a broad shift in cellular energy metabolism—from storage to usage—much like what happens during aerobic training.
SLU-PP-332 has been shown to reproduce many of the cellular and physiological changes seen in physically trained animals. In mouse studies, SLU-PP-332 led to:
Increased running endurance
Improved VO₂ max
Enhanced capillary density in muscle
Shift toward oxidative muscle fibers
Higher mitochondrial content
It essentially transforms “sedentary” muscles into metabolically active, endurance-ready tissue—even without physical training.
In models of diet-induced obesity, SLU-PP-332 produced:
Reduction in white adipose tissue (WAT)
Lower fasting insulin and glucose
Improved glucose tolerance
Reversal of hepatic steatosis
Reduced inflammation in liver and adipose tissue
This suggests it can be highly effective for those struggling with:
Insulin resistance
Fatty liver (NAFLD/NASH)
Obesity
PCOS and metabolic syndrome
Mitochondrial dysfunction is at the root of many chronic diseases and the aging process. SLU-PP-332 has demonstrated the ability to:
Increase mitochondrial density
Restore oxidative phosphorylation efficiency
Enhance ATP production
Reduce mitochondrial DNA damage
Upregulate mitophagy (removal of damaged mitochondria)
This makes SLU-PP-332 especially valuable in aging populations or anyone with chronic fatigue, fibromyalgia, or neurodegenerative risk.
In preclinical heart failure and ischemia-reperfusion models, SLU-PP-332 has shown:
Improved cardiac contractility
Lower cardiomyocyte apoptosis
Enhanced fatty acid oxidation in cardiac tissue
Reduced pathologic remodeling and fibrosis
These findings suggest potential future use in:
Heart failure with preserved or reduced ejection fraction (HFpEF / HFrEF)
Cardiac ischemia recovery
Post-infarct metabolic support
SLU-PP-332 suppresses age-associated inflammatory markers like:
IL-6
TNF-α
CRP
It also supports autophagy, mitophagy, and fibrosis attenuation in organs like the liver, heart, and kidney—critical factors in aging.
